MAIA Biotechnology Inc. Common Stock (MAIA)

About MAIA

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

13

Website

maiabiotech.com/

Fundamentals

1-day range

$1.32$1.38

Market cap

$80.26M

P/E (trailing)

—

P/E (forward)

1.20

EPS (trailing)

$-0.68

Dividend yield

—

Beta

0.27

Avg. volume

660.3K

Forecasts

2 analyst ratings

MAIA Biotechnology Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MAIA

  MAIA Biotechnology Inc. Common Stock

  $1.33

  ▼ 3.99%
  Market cap $80.26MP/E —
  $0.87$3.19
• TELO

  Telomir Pharmaceuticals Inc. Common Stock

  $1.14

  ▼ 4.20%
  Market cap $80.47MP/E —
  $0.8884$2.09
• ATHE

  Alterity Therapeutics Limited American Depositary Shares

  $4.51

  ▼ 1.10%
  Market cap $80.78MP/E —
  $0.01$0.785
• NMAD

  Nomad Power Solutions Inc. Common Stock

  $4.33

  ▼ 2.04%
  Market cap $81.57MP/E —
  $3.12$7.7
• LFVN

  Lifevantage Corporation Common Stock (Delaware)

  $6.6

  ▲ 2.33%
  Market cap $83.01MP/E 14.23
  $3.9$14.28
• GANX

  Gain Therapeutics Inc. Common Stock

  $1.78

  ▼ 3.78%
  Market cap $74.64MP/E —
  $1.53$4.34
• ACET

  Adicet Bio Inc. Common Stock

  $9.05

  ▲ 0.44%
  Market cap $86.38MP/E —
  $6.01$17.44

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• MAIA Biotechnology Files $150M Mixed Shelf Offering
  benzinga · 8/21/2026
• MAIA Biotechnology Files $150M Mixed Shelf Offering
  Benzinga · 8/21/2026
• Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
  Yahoo · 8/17/2026
• MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
  Benzinga · 8/10/2026

• Guerrero Ramiro · August 24, 2026 · Buy

  1.8K @ $1.33
• Guerrero Ramiro · August 20, 2026 · Buy

  11.9K @ $1.37
• Guerrero Ramiro · June 30, 2026 · Grant

  26.4K
• Ngar Yee Louie · June 30, 2026 · Grant

  32.6K
• Cristian Luput · June 30, 2026 · Grant

  27.6K
• Stan Smith · June 30, 2026 · Grant

  32.0K
• Theagene Jean-Manasse · June 30, 2026 · Grant

  26.4K
• Steven M. Chaouki · June 30, 2026 · Grant

  27.0K
• Vlad Vitoc · June 1, 2026 · Buy

  72.7K @ $1.39
• Stan Smith · June 1, 2026 · Buy

  75.0K @ $1.34
• Sergei Gryaznov · June 1, 2026 · Buy

  2.0K @ $1.35
• Vlad Vitoc · May 29, 2026 · Grant

  800.0K
• Sergei Gryaznov · May 29, 2026 · Grant

  400.0K
• Himmelreich Jeffrey C · May 29, 2026 · Grant

  60.0K
• Vlad Vitoc · April 10, 2026 · Grant

  800.0K

Institutional Ownership

March 31, 2026

Total shares held

12.91M

Total value held

$18.05M

Institutional holders

30